Advisor Partners Has Boosted By $364,182 Its Johnson & Johnson (JNJ) Holding; Inflarx N.V. (IFRX) Shorts Lowered By 1.57% – The FinReviewer

Johnson & Johnson (NYSE:JNJ) Logo

Inflarx N.V. (NASDAQ:IFRX) had a decrease of 1.57% in short interest. IFRX’s SI was 231,600 shares in January as released by FINRA. Its down 1.57% from 235,300 shares previously. With 11,900 avg volume, 20 days are for Inflarx N.V. (NASDAQ:IFRX)’s short sellers to cover IFRX’s short positions. The SI to Inflarx N.V.’s float is 3.2%. The stock decreased 4.04% or $1.47 during the last trading session, reaching $34.9. About 49,316 shares traded or 12.30% up from the average. InflaRx N.V. (NASDAQ:IFRX) has risen 63.49% since January 2, 2018 and is uptrending. It has outperformed by 63.49% the S&P500. Some Historical IFRX News: 17/05/2018 – INFLARX NV – CASH POSITION APPROXIMATELY US$137 MLN (EUR 115 MLN) AS OF MARCH 31, 2018; 08/03/2018 InflaRx announces first patient enrolled in Phase IIb trial with lead candidate IFX-1 in Hidradenitis Suppurativa; 29/03/2018 – lnflaRx Full Year 2017 Financial & Operating Results; 08/03/2018 – INFLARX ANNOUNCES FIRST PATIENT ENROLLED IN PHASE llB TRIAL WITH LEAD CANDIDATE IFX-1 IN HIDRADENITIS SUPPURATIVA; 08/05/2018 – InflaRx N.V. Announces Closing of Primary and Secondary Offering of Common Shrs; 17/05/2018 – InflaRx 1Q Loss EUR10.3M; 03/05/2018 – INFLARX PRIMARY, SECONDARY OFFERINGS PRICES AT $34.00 PER SHARE; 29/03/2018 – InflaRx Full Year 2017 Financial & Operating Results; 29/03/2018 – InflaRx FY Loss/Shr EUR2.6; 08/05/2018 – INFLARX N.V. REPORTS CLOSING OF PRIMARY, SECONDARY OFFERING

Advisor Partners Llc increased Johnson & Johnson (JNJ) stake by 3.84% reported in 2018Q3 SEC filing. Advisor Partners Llc acquired 2,639 shares as Johnson & Johnson (JNJ)’s stock rose 5.87%. The Advisor Partners Llc holds 71,409 shares with $9.87M value, up from 68,770 last quarter. Johnson & Johnson now has $342.62 billion valuation. The stock decreased 1.01% or $1.3 during the last trading session, reaching $127.75. About 6.65M shares traded. Johnson & Johnson (NYSE:JNJ) has risen 3.75% since January 2, 2018 and is uptrending. It has outperformed by 3.75% the S&P500. Some Historical JNJ News: 16/03/2018 – JOHNSON & JOHNSON ANNOUNCES BINDING OFFER FROM PLATINUM EQUITY TO ACQUIRE LIFESCAN, INC; 11/04/2018 – J&J, Imerys Ordered to Pay Punitive $80 Million in Talc Case; 16/04/2018 – J&J SAYS ESKETAMINE PRIMARY EFFICACY ENDPOINT WAS ACHIEVED; 04/04/2018 – J&J Jury Set to Weigh Banker’s Claims Baby Powder Caused Cancer; 22/03/2018 – EpigenCare Named as Johnson & Johnson Innovation Finalist in Skincare Challenge; 16/03/2018 – Platinum Equity Submits Binding Offer to Acquire LifeScan From Johnson & Johnson; 22/05/2018 – J&J Re-Launches Baby Care Line Amid Growing Consumer Concerns About Cancer-Causing Talc; 20/03/2018 – DOMINIC J. CARUSO TO RETIRE AS CFO OF JOHNSON & JOHNSON; 18/05/2018 – Johnson & Johnson scraps Alzheimer’s trials on safety concerns; 16/03/2018 – RPT-J&J says offered $2.1 bln for Lifescan diabetes business

InflaRx GmbH, a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology in the United States. The company has market cap of $895.61 million. The Company’s C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. It currently has negative earnings. The firm is involved developing IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and other chronic/autoimmune diseases, as well as IFX-2 for the treatment of chronic inflammation and autoimmune diseases.

More notable recent InflaRx N.V. (NASDAQ:IFRX) news were published by: which released: “InflaRx Receives European Approval to Initiate Phase II Clinical Trial with IFX-1 in ANCA-Associated Vasculitis – Nasdaq” on December 19, 2018, also with their article: “50 Biggest Movers From Monday – Benzinga” published on January 02, 2019, published: “Barrick-Randgold Merger Consummated as Trading Starts in New Company’s Shares – Nasdaq” on January 02, 2019. More interesting news about InflaRx N.V. (NASDAQ:IFRX) were released by: and their article: “Mid-Afternoon Market Update: Dow Up 175 Points; Pulmatrix Shares Plunge – Benzinga” published on December 31, 2018 as well as‘s news article titled: “Wavefront Announces Audited and Fourth Quarter 2018 Financial Results – Nasdaq” with publication date: December 31, 2018.

Since August 27, 2018, it had 3 buys, and 8 sales for $79.44 million activity. Another trade for 29,000 shares valued at $3.91M was made by Sneed Michael E on Monday, August 27. $536,638 worth of Johnson & Johnson (NYSE:JNJ) was sold by Kapusta Ronald A. 40,000 shares valued at $5.77 million were sold by Duato Joaquin on Wednesday, November 7. Fasolo Peter sold $24.41M worth of Johnson & Johnson (NYSE:JNJ) on Monday, December 3. PRINCE CHARLES bought $268,731 worth of stock or 2,000 shares. On Friday, November 16 the insider Gorsky Alex sold $38.60M. $133,910 worth of Johnson & Johnson (NYSE:JNJ) was bought by PEREZ WILLIAM D on Friday, December 14.

More notable recent Johnson & Johnson (NYSE:JNJ) news were published by: which released: “Johnson & Johnson (NYSE:JNJ) 2019 – Live Trading News” on January 02, 2019, also with their article: “Johnson & Johnson: Weak Sign – Seeking Alpha” published on December 19, 2018, published: “4 Top Stock Trades for Monday: GE, TSLA, Gold, JNJ –” on December 28, 2018. More interesting news about Johnson & Johnson (NYSE:JNJ) were released by: and their article: “Why I Had To Buy Johnson & Johnson – Seeking Alpha” published on December 19, 2018 as well as‘s news article titled: “J&J extends baby powder crisis slump – Seeking Alpha” with publication date: December 17, 2018.

Investors sentiment increased to 1.05 in 2018 Q3. Its up 0.08, from 0.97 in 2018Q2. It increased, as 43 investors sold JNJ shares while 748 reduced holdings. 115 funds opened positions while 719 raised stakes. 1.70 billion shares or 7.91% less from 1.84 billion shares in 2018Q2 were reported. Baldwin Brothers Incorporated Ma owns 39,522 shares. Arete Wealth Advsrs Limited Liability Corp owns 15,889 shares. Johnson Counsel holds 0.71% of its portfolio in Johnson & Johnson (NYSE:JNJ) for 230,447 shares. 38,973 are held by Northpointe Limited Liability Corporation. Noesis Cap Mangement holds 0.51% of its portfolio in Johnson & Johnson (NYSE:JNJ) for 10,594 shares. 281,800 were accumulated by Old Republic Interest Corporation. Michigan-based Lvm Capital Management Ltd Mi has invested 3.81% in Johnson & Johnson (NYSE:JNJ). Kepos LP has 48,609 shares for 0.34% of their portfolio. Silvercrest Asset Management Gp Limited Liability Corp owns 693,497 shares. Bright Rock Management Limited invested in 43,241 shares or 1.95% of the stock. Investec Asset Mngmt Ltd invested 2.87% of its portfolio in Johnson & Johnson (NYSE:JNJ). Camarda Financial Advsrs Ltd Liability Corp accumulated 2,575 shares. Dodge And Cox invested in 0% or 31,690 shares. Pennsylvania-based Clark Capital Gru has invested 1.35% in Johnson & Johnson (NYSE:JNJ). Northwest Inv Counselors Lc has invested 1.93% in Johnson & Johnson (NYSE:JNJ).

Among 5 analysts covering Johnson u0026 Johnson (NYSE:JNJ), 2 have Buy rating, 0 Sell and 3 Hold. Therefore 40% are positive. Johnson u0026 Johnson had 5 analyst reports since July 12, 2018 according to SRatingsIntel. Morgan Stanley maintained it with “Equal-Weight” rating and $153 target in Thursday, October 11 report. The company was maintained on Wednesday, October 17 by Credit Suisse. The firm earned “Outperform” rating on Wednesday, October 17 by Raymond James. The company was upgraded on Thursday, July 12 by Goldman Sachs. The firm earned “Neutral” rating on Monday, October 22 by Citigroup.

Johnson & Johnson (NYSE:JNJ) Institutional Positions Chart

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *